Arcus Biosciences (RCUS) Competitors $8.70 +0.14 (+1.64%) As of 05/19/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RCUS vs. PTCT, SRPT, RNA, SWTX, RARE, AKRO, ACLX, ZLAB, VKTX, and CRNXShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include PTC Therapeutics (PTCT), Sarepta Therapeutics (SRPT), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), Arcellx (ACLX), Zai Lab (ZLAB), Viking Therapeutics (VKTX), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. PTC Therapeutics Sarepta Therapeutics Avidity Biosciences SpringWorks Therapeutics Ultragenyx Pharmaceutical Akero Therapeutics Arcellx Zai Lab Viking Therapeutics Crinetics Pharmaceuticals Arcus Biosciences (NYSE:RCUS) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Which has preferable valuation and earnings, RCUS or PTCT? Arcus Biosciences has higher earnings, but lower revenue than PTC Therapeutics. Arcus Biosciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$141M6.59-$307M-$4.19-2.10PTC Therapeutics$1.77B2.10-$626.60M$6.517.21 Does the MarketBeat Community believe in RCUS or PTCT? PTC Therapeutics received 377 more outperform votes than Arcus Biosciences when rated by MarketBeat users. However, 65.57% of users gave Arcus Biosciences an outperform vote while only 62.11% of users gave PTC Therapeutics an outperform vote. CompanyUnderperformOutperformArcus BiosciencesOutperform Votes20065.57% Underperform Votes10534.43% PTC TherapeuticsOutperform Votes57762.11% Underperform Votes35237.89% Does the media favor RCUS or PTCT? In the previous week, PTC Therapeutics had 7 more articles in the media than Arcus Biosciences. MarketBeat recorded 14 mentions for PTC Therapeutics and 7 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.48 beat PTC Therapeutics' score of 0.69 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in RCUS or PTCT? 92.9% of Arcus Biosciences shares are held by institutional investors. 12.3% of Arcus Biosciences shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is RCUS or PTCT more profitable? PTC Therapeutics has a net margin of -50.32% compared to Arcus Biosciences' net margin of -102.66%. PTC Therapeutics' return on equity of 0.00% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-102.66% -45.59% -22.38% PTC Therapeutics -50.32%N/A -16.44% Do analysts rate RCUS or PTCT? Arcus Biosciences presently has a consensus price target of $25.67, indicating a potential upside of 192.33%. PTC Therapeutics has a consensus price target of $61.92, indicating a potential upside of 31.86%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcus Biosciences is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91PTC Therapeutics 1 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has more volatility and risk, RCUS or PTCT? Arcus Biosciences has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. SummaryArcus Biosciences beats PTC Therapeutics on 10 of the 18 factors compared between the two stocks. Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$929.67M$6.51B$5.41B$19.72BDividend YieldN/A2.67%5.22%3.84%P/E Ratio-2.799.1727.0435.27Price / Sales6.59251.58393.5334.16Price / CashN/A65.8538.2517.51Price / Book1.426.516.804.77Net Income-$307M$143.73M$3.23B$1.02B7 Day Performance-0.40%2.64%2.54%0.77%1 Month Performance11.35%9.36%10.78%10.35%1 Year Performance-48.05%-4.13%15.57%5.21% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences3.7195 of 5 stars$8.70+1.6%$25.67+195.0%-48.5%$921.20M$141M-2.76500Positive NewsPTCTPTC Therapeutics4.2452 of 5 stars$46.01+4.0%$61.92+34.6%+41.9%$3.65B$1.77B-7.751,410Trending NewsSRPTSarepta Therapeutics4.784 of 5 stars$36.37+0.3%$131.22+260.8%-71.1%$3.57B$2.23B29.10840Gap UpHigh Trading VolumeRNAAvidity Biosciences1.9339 of 5 stars$29.33+5.2%$66.38+126.3%+2.4%$3.53B$10.90M-10.18190Options VolumeSWTXSpringWorks Therapeutics2.3633 of 5 stars$46.12-0.3%$52.57+14.0%+3.2%$3.46B$191.59M-13.25230Positive NewsHigh Trading VolumeRAREUltragenyx Pharmaceutical4.4429 of 5 stars$36.09+2.8%$90.93+152.0%-13.6%$3.32B$590.69M-5.691,310Positive NewsAKROAkero Therapeutics3.898 of 5 stars$41.53+4.2%$76.29+83.7%+91.5%$3.31BN/A-11.0730Insider TradeHigh Trading VolumeACLXArcellx1.8289 of 5 stars$59.50+3.4%$109.31+83.7%+9.1%$3.28B$76.81M-83.8080Positive NewsZLABZai Lab2.6421 of 5 stars$29.40+0.5%$47.37+61.1%+70.1%$3.24B$418.33M-10.611,950Gap UpVKTXViking Therapeutics4.4801 of 5 stars$28.30+2.7%$87.15+208.0%-59.0%$3.18BN/A-28.3020Positive NewsGap DownCRNXCrinetics Pharmaceuticals3.704 of 5 stars$33.32+8.6%$73.00+119.1%-39.8%$3.12B$1.04M-8.93210 Related Companies and Tools Related Companies PTC Therapeutics Competitors Sarepta Therapeutics Competitors Avidity Biosciences Competitors SpringWorks Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Akero Therapeutics Competitors Arcellx Competitors Zai Lab Competitors Viking Therapeutics Competitors Crinetics Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RCUS) was last updated on 5/20/2025 by MarketBeat.com Staff From Our PartnersThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s treachery A shocking bill has been put before the House of Representatives… Representative Brandon Gill wants Preside...Porter & Company | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredAI Firm Enters America's Largest Medicaid MarketNew York's $95B system just approved a new AI healthcare platform. Here's what to know. A major shift in U....i2i Marketing Group, LLC | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.